Human stem and progenitor cells have been shown to engraft in the marrow and spleen of sublethally irradiated NOD/SCID, sCID, Bg Nude/XID, NOD/SCID r chain""" (NSG) mice and in fetal organs xenografted in NOD/SCID (SCID/Hu) mice [1]. In some studies, optimal engraftment required administration of specific recombinant human growth factors [2]. Nevertheless, the demonstration of multilineage hematopoiesis in NOD/SCID mice transplanted with isolated human CD34+/CD38- "stem" cells supports the notion that xenogeneic transplantation in immunodeficient mice may serve as a surrogate model for human transplantation. Given the importance of preclinical in vivo models, the purpose of Core E is to provide CCEH members as well as other UW and FHCRC investigators with the resources and expertise needed to execute xenografting studies in immune deficient mice. The majority of studies involve analysis of hematopoietic reconstituting ability or immune function of defined populations of cells from humans, non-human primates, and dogs. Protocols have also been developed for evaluating the teratoma generating potential of ESC and iPSC, as well as the engraftment and regenerative potential of their derived progeny. Specifically Core E provides: 1) age appropriate NOD/SCID mice through an in-house breeding program, 2) expert consultation on experimental design, 3) help with obtaining lACUC approval, and 4) assistance with and/or full responsibility for conditioning and injecting mice, as well as sampling tissues from live and euthanized animals.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1-GRB-G)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Busch, S E; Moser, R D; Gurley, K E et al. (2014) ARF inhibits the growth and malignant progression of non-small-cell lung carcinoma. Oncogene 33:2665-73
Watts, Korashon L; Beard, Brian C; Wood, Brent L et al. (2014) No evidence of clonal dominance after transplant of HOXB4-expanded cord blood cells in a nonhuman primate model. Exp Hematol 42:497-504
Klippel, Z K; Chou, J; Towlerton, A M et al. (2014) Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC. Gene Ther 21:337-42
Wurm, Melanie; Kowalski, John; Heckl, Dirk et al. (2014) Ectopic expression of HOXC6 blocks myeloid differentiation and predisposes to malignant transformation. Exp Hematol 42:114-25.e4
Adair, Jennifer E; Johnston, Sandra K; Mrugala, Maciej M et al. (2014) Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. J Clin Invest 124:4082-92
Iwata, Mineo; Sandstrom, Richard S; Delrow, Jeffrey J et al. (2014) Functionally and phenotypically distinct subpopulations of marrow stromal cells are fibroblast in origin and induce different fates in peripheral blood monocytes. Stem Cells Dev 23:729-40
Green, Damian J; Orgun, Nural N; Jones, Jon C et al. (2014) A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. Cancer Res 74:1179-89
Burtner, Christopher R; Beard, Brian C; Kennedy, Douglas R et al. (2014) Intravenous injection of a foamy virus vector to correct canine SCID-X1. Blood 123:3578-84
Bleakley, Marie; Heimfeld, Shelly; Jones, Lori A et al. (2014) Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells. Biol Blood Marrow Transplant 20:705-16
Shu, Z; Heimfeld, S; Gao, D (2014) Hematopoietic SCT with cryopreserved grafts: adverse reactions after transplantation and cryoprotectant removal before infusion. Bone Marrow Transplant 49:469-76

Showing the most recent 10 out of 175 publications